Oaks Joshua, Ogretmen Besim
Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina , Charleston, SC , USA.
Front Oncol. 2015 Jan 15;4:388. doi: 10.3389/fonc.2014.00388. eCollection 2014.
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that is a primary regulator of cellular proliferation through targeting of proliferative kinases, cell cycle regulators, and apoptosis inhibitors. It is through the regulation of these regulatory elements that gives PP2A tumor suppressor functions. In addition to mutations on the regulatory subunits, the phosphatase/tumor suppressing activity of PP2A is also inhibited in several cancer types due to overexpression or modification of the endogenous PP2A inhibitors such as SET/I2PP2A. This review focuses on the current literature regarding the interactions between the lipid signaling molecules, selectively sphingolipids, and the PP2A inhibitor SET for the regulation of PP2A, and the therapeutic potential of sphingolipids as PP2A activators for tumor suppression via targeting SET oncoprotein.
蛋白磷酸酶2A(PP2A)是一种丝氨酸/苏氨酸磷酸酶,它通过靶向增殖激酶、细胞周期调节因子和凋亡抑制剂,成为细胞增殖的主要调节因子。正是通过对这些调节元件的调控,赋予了PP2A肿瘤抑制功能。除了调节亚基上的突变外,由于内源性PP2A抑制剂如SET/I2PP2A的过表达或修饰,PP2A的磷酸酶/肿瘤抑制活性在几种癌症类型中也受到抑制。本综述聚焦于当前有关脂质信号分子(特别是鞘脂)与PP2A抑制剂SET之间相互作用以调节PP2A的文献,以及鞘脂作为PP2A激活剂通过靶向SET癌蛋白抑制肿瘤的治疗潜力。